Abstract: Substituted 1-alkylamino-1H-indazoles for lowering intraocular pressure and treating glaucoma are disclosed.

Abstract: Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H1 antagonist and an anti-TNF? compound.

Abstract: Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient.

Abstract: The present invention relates to a brake fluid valve assembly (12). Assembly (12) comprises a housing (14) defining an inner chamber (21). A first non-return valve (32) and a second non-return valve (33) are arranged in the chamber (21). The housing (14) defines an inlet (22) and outlets (23, 24). Assembly (12) also comprises feed port means (34) arranged to allow fluid to flow from the inlet (22) to the first non-return valve (32). The first non-return valve (32) is arranged to let fluid flow from a master cylinder (11) through the inlet (22) and through the outlets (23, 24) towards a caliper (1) to apply a brake. Return port means (50) are arranged to allow fluid to flow from the outlets (23, 24) to the second non-return valve (33). The second non-return valve (33) is arranged to let fluid flow from a caliper through the outlets (23, 24) and through the inlet (22) towards a master cylinder (11). The assembly also comprises a restrictor port (52) between the outlet and the second non-return valve.

Abstract: Novel dioxinoindazole compounds and dioxoloindazole compounds are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions of one or more of the compounds of the present invention.

Abstract: A filter and method for filtering an optical beam are disclosed. One embodiment of the filter is an optical filter for filtering an incident light beam, comprising an optically effective material characterized by: a light transmittance of less than 1% for wavelengths below 420 nm; and a light transmittance for wavelengths complementary and near complementary to wavelengths below 420 nm that, combined with the transmittance for wavelengths below 420 nm, will yield a filtered light beam having a luminosity of about 90% and an excitation purity of 5% or less. The complementary wavelengths can be wavelengths above about 640 nm, wavelengths above about 660 nm, and/or wavelengths from about 540 nm to about 560 nm. Further, in one embodiment the difference between the light transmittance just below 420 nm and the light transmittance just above 420 nm can be greater than 90%. Above 420 nm, in some embodiments, the light transmittance can be arbitrarily determined.

Abstract: Disclosed are UV absorbers that contain a labile functional group capable of initiating free radical polymerization.

Abstract: Embodiments of the present invention provide a fundus lens. This fundus lens includes a first aspheric lens and a second aspheric lens and a diffractive optical element. This diffractive optical element is placed between the first and second aspheric lens and illuminated by an off access light source. The diffractive optical element contains a predetermined pattern which may be directed and imaged on a fundus. The first and second aspheric lenses are operable to gather light scattered by the fundus and provide the gathered light to a fundus camera. This fundus camera may then be operable to process the gathered light and determine the topography of the fundus.

Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.

Abstract: RNA interference is provided for inhibition of aquaporin 4 (AQP4) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.

Abstract: Coated medical implants have an implant body configured for securing in or adjacent to body tissue of a patient. The implant body has an implant surface and a coating is formed on at least a portion of the implant surface. The coating includes a coating outer surface of a first chemical component that is chemically bonded to a carboxylate functionality of a second chemical component. The second chemical component is immobilized by amide linkage to an underlying third chemical component that is plasma coated directly onto implant body surfaces. The coating either inhibits or prevents the adhesion of protein and/or cellular proliferation or may be a non-fouling coating.

Abstract: Topical ophthalmic solution compositions of gatifloxacin are disclosed. The compositions do not contain disodium edetate or any other metal chelating agent.

Abstract: RNA interference is provided for inhibition of aquaporin 4 (AQP4) to treat conditions associated with neovascularization.

Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.

Abstract: The present invention provides methods and kits for diagnosing and treating glaucoma.

Abstract: The present invention relates to the use of thy1-FP (fluorescent protein) non-human transgenic animals such as mice to screen for ophthalmic agents that can be used to treat corneal dry eye syndrome and/or retinal neuropathies associated with glaucoma and/or age-related macular degeneration. Such ophthalmic agents may be selected by assessing their ability to provide protection in ocular tissue.

Abstract: The present invention concerns implantable ocular devices for the sustained release of medication to the eye, and methods for manufacturing and using such devices. In one embodiment, the present invention provides a device comprising: (a) a body comprising a matrix of a prostaglandin and a silicone; (b) a parylene coating on the outer surface of the body; and (c) one or more pores extending from the outer surface of the parylene coating to the outer surface of the body.

Abstract: The present invention provides methods and kits for diagnosing and treating glaucoma.

Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Abstract: The present invention is directed to an improved process for producing substantially pure fluorescein, as well as to substantially pure fluorescein compositions prepared by the process. The invention is particularly directed to the provision of pharmaceutical compositions for use in angiography. The substantially pure fluorescein produced by the process of the present invention is low in color, low in sodium chloride content, and substantially free of pyridine.